Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.
Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ; Australian Ovarian Cancer Study Group; Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD. Helland Å, et al. Among authors: pearson rb. PLoS One. 2011 Apr 13;6(4):e18064. doi: 10.1371/journal.pone.0018064. PLoS One. 2011. PMID: 21533284 Free PMC article.
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, Cullinane C, Etemadmoghadam D, Ftouni S, Galletta L, Anglesio MS, Hendley J, Bowes L, Sheppard KE, Christie EL, Pearson RB, Harnett PR, Heinzelmann-Schwarz V, Friedlander M, McNally O, Quinn M, Campbell P, deFazio A, Bowtell DD; Australian Ovarian Cancer Study. Cowin PA, et al. Among authors: pearson rb. Cancer Res. 2012 Aug 15;72(16):4060-73. doi: 10.1158/0008-5472.CAN-12-0203. Cancer Res. 2012. PMID: 22896685
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Davis SJ, Sheppard KE, Anglesio MS, George J, Traficante N, Fereday S, Intermaggio MP, Menon U, Gentry-Maharaj A, Lubinski J, Gronwald J, Pearce CL, Pike MC, Wu A, Kommoss S, Pfisterer J, du Bois A, Hilpert F, Ramus SJ, Bowtell DD, Huntsman DG, Pearson RB, Simpson KJ, Campbell IG, Gorringe KL. Davis SJ, et al. Among authors: pearson rb. Mol Cancer Ther. 2015 Jun;14(6):1495-503. doi: 10.1158/1535-7163.MCT-15-0039. Epub 2015 Apr 7. Mol Cancer Ther. 2015. PMID: 25852062
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD. Au-Yeung G, et al. Among authors: pearson rb. Clin Cancer Res. 2017 Apr 1;23(7):1862-1874. doi: 10.1158/1078-0432.CCR-16-0620. Epub 2016 Sep 23. Clin Cancer Res. 2017. PMID: 27663592 Free PMC article.
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS); deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL. Kondrashova O, et al. Among authors: pearson rb. Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z. Nat Commun. 2018. PMID: 30266954 Free PMC article.
Second AKT: the rise of SGK in cancer signalling.
Bruhn MA, Pearson RB, Hannan RD, Sheppard KE. Bruhn MA, et al. Among authors: pearson rb. Growth Factors. 2010 Dec;28(6):394-408. doi: 10.3109/08977194.2010.518616. Epub 2010 Oct 5. Growth Factors. 2010. PMID: 20919962 Review.
Targeting PI3 kinase/AKT/mTOR signaling in cancer.
Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA. Sheppard K, et al. Among authors: pearson rb. Crit Rev Oncog. 2012;17(1):69-95. doi: 10.1615/critrevoncog.v17.i1.60. Crit Rev Oncog. 2012. PMID: 22471665 Review.
Unexpected role of CDK4 in a G2/M checkpoint.
Sheppard KE, Pearson RB, Hannan RD. Sheppard KE, et al. Among authors: pearson rb. Cell Cycle. 2015;14(9):1351-2. doi: 10.1080/15384101.2015.1022060. Cell Cycle. 2015. PMID: 25790252 Free PMC article. No abstract available.
AKT-independent PI3-K signaling in cancer - emerging role for SGK3.
Bruhn MA, Pearson RB, Hannan RD, Sheppard KE. Bruhn MA, et al. Among authors: pearson rb. Cancer Manag Res. 2013 Aug 26;5:281-92. doi: 10.2147/CMAR.S35178. eCollection 2013. Cancer Manag Res. 2013. PMID: 24009430 Free PMC article. Review.
154 results